Market News AIOpen the app

ABCL stock news · AbCellera Biologics

Stories about AbCellera Biologics (ABCL) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ABCL

Follow AbCellera Biologics (ABCL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ABCL
Free on the App Store and Google Play, or on the web.
  1. Nov 9, 2026, 7:35 PM ET · Results

    AbCellera Biologics Q3 2026 Earnings Call Transcript

    Good for ABCL

    AbCellera reported that ABCL635 reduced hot flashes by 5.3 events per day versus placebo after 4 weeks, alongside a $41 million loss. The trial result makes the update favorable.

  2. Aug 12, 2026, 2:00 PM ET · Market

    AbCellera Biologics stock experiences significant movement on Wednesday.

    Neutral

    AbCellera Biologics shares surged following the announcement of positive Phase 2 clinical trial results for its treatment ABCL635, which sets a new efficacy benchmark for alleviating menopausal hot flashes. This news, coupled with a $200 million capital raise to fund further development, positions the company favorably in the healthcare sector.